-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 HYLCCCtG+Xvr8w+M7E+MFOkbOtQqj7I1DlnwyEuZxSU1GnABaXXa4sZHVundKP2U
 Dw/nryXUdNy8Kn49E9kuww==

<SEC-DOCUMENT>0001299933-10-001600.txt : 20100423
<SEC-HEADER>0001299933-10-001600.hdr.sgml : 20100423
<ACCEPTANCE-DATETIME>20100423150419
ACCESSION NUMBER:		0001299933-10-001600
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100420
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20100423
DATE AS OF CHANGE:		20100423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		10767095

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htm_37253.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> Cumberland Pharmaceuticals Inc. (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<!-- Comment1 -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	April 20, 2010
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	Cumberland Pharmaceuticals Inc.
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Tennessee
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	001-33637
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	62-1765329
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	2525 West End Avenue, Suite 950, Nashville, Tennessee
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	37203
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	(615) 255-0068
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 5.07 Submission of Matters to a Vote of Security Holders.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
On April 20, 2010, the annual meeting of shareholders of Cumberland Pharmaceuticals Inc. (the "Company") was held in Nashville, Tennessee.  The following matters were voted upon and approved by the Company's shareholders:<br><br>(1) the election of five members to the Board of Directors and <br><br>(2) the ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm.<br><br>At the meeting, A.J. Kazimi (12,340,593 votes for, 1,709,376 votes withheld and 1,495,646 broker non-votes), Martin E. Cearnal (11,538,722 votes for, 2,511,247 votes withheld and 1,495,646 broker non-votes) and Gordon R. Bernard (12,174,693 votes for, 1,875,276 votes withheld and 1,495,646 broker non-votes) were each elected to serve as a member of the Board of Directors until the 2013 annual meeting of shareholders.  Jonathan Griggs (12,206,485 votes for, 1,843,484 votes withheld and 1,495,646 broker non-votes) was elected to serve as a member of the Board of Directors until the 2011 annual m
eeting of shareholders.  James Jones (13,897,108 votes for, 152,861 votes withheld and 1,495,646 broker non-votes) was elected to serve as a member of the Board of Directors until the 2012 annual meeting of shareholders. <br><br>In addition to the election of directors, the shareholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm (15,481,781 votes for, 31,297 votes against and 32,537 votes abstained).
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 8.01 Other Events.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
On April 20, 2010, the Company issued a press release announcing the election of Gordon R. Bernard, M.D., Jonathan Griggs and James Jones to the Board of Directors.  Previously, Dr. Bernard served as Senior Vice President and Medical Director of the Company and Mr. Griggs served as a member of the Company's Pharmaceutical Advisory Board.  A copy of the press release is furnished as Exhibit 99.1.
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><P ALIGN="LEFT" STYLE="FONT-SIZE: 10PT"></P><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	Cumberland Pharmaceuticals Inc.
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	April 23, 2010
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	David L. Lowrance
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: David L. Lowrance
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: Chief Financial Officer
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Press release dated April 20, 2010.
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt"><img src="e29814-10111153949103c96e_1.jpg">
</FONT>

<P align="center" style="font-size: 12pt"><B>CUMBERLAND PHARMACEUTICALS ADDS THREE TO BOARD</B>



<P align="center" style="font-size: 12pt"><B>WITH NEW ELECTIONS AT ANNUAL SHAREHOLDER MEETING</B>



<P align="left" style="font-size: 12pt"><B>NASHVILLE, Tenn., April&nbsp;20, 2010 &#150; </B>Shareholders of <B>Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)</B>
today elected Gordon R. Bernard, M.D., Jonathan Griggs, and James Jones as new members of the
company&#146;s Board of Directors at its annual meeting. Directors A.J. Kazimi and Martin E. Cearnal
were also re-elected.


<P align="left" style="font-size: 12pt">Gordon Bernard, M.D. is Assistant Vice-Chancellor for Research at Vanderbilt University and Medical
Director of Vanderbilt&#146;s Institutional Review Board. He is also the Melinda Owen Bass Professor of
Medicine of Vanderbilt&#146;s Division of Allergy, Pulmonary and Critical Care Medicine. Dr.&nbsp;Bernard is
internationally renowned for his contributions to clinical research, particularly in the area of
critical care medicine. He has served as the Steering Committee Chair for the National Institutes
of Health&#146;s Acute Respiratory Distress Syndrome Clinical Trials Network since 1994. Dr.&nbsp;Bernard
moves to the board from his previous role as Cumberland&#146;s Medical Director, a position he has held
since the company&#146;s inception in 1999.


<P align="left" style="font-size: 12pt">Jonathan Griggs is a pharmaceutical industry veteran with more than 40&nbsp;years of experience. He
spent 23&nbsp;years at Warner Lambert Corporation where he served as Vice President of Human Resources,
providing leadership during the company&#146;s integration of three pharmaceutical companies into what
became Parke Davis. Since 1992, he has served as CEO of Griggs & Associates, a management and human
resources consulting firm providing assistance to a variety of healthcare and other companies. Mr.
Griggs has been a member of Cumberland&#146;s pharmaceutical advisory board since 1999.


<P align="left" style="font-size: 12pt">James Jones spent 35&nbsp;years in professional accounting at KPMG LLP, culminating in his role as
Managing Partner for the company&#146;s middle Tennessee operations from 1999 until his retirement in
2006. During his tenure with KPMG, Mr.&nbsp;Jones let a team of more than 100 individuals providing
accounting services for an extensive client base. Following his retirement Mr.&nbsp;Jones has served as
advisor to several KPMG client companies, including a role as interim CEO for one organization. He
currently serves on the board of Aegis Sciences Corporation, a federally certified forensic
toxicology laboratory, where he also chairs the audit committee.


<P align="left" style="font-size: 12pt">&#147;We are honored to welcome these highly qualified individuals to our board of directors,&#148; said A.J.
Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. &#147;Each brings significant experience
in an area critical to our company&#146;s continued growth and success, and we know Cumberland will
benefit from their guidance.&#148;


<P align="left" style="font-size: 12pt">Mr.&nbsp;Kazimi, who has served as Cumberland&#146;s Chief Executive Officer since inception, also was
re-elected along with the company&#146;s Chief Commercial Officer Martin Cearnal. The company&#146;s other
directors include Thomas R. Lawrence, Robert G. Edwards, M.D. and Dr.&nbsp;Lawrence W. Greer.


<P align="left" style="font-size: 12pt">SOURCE: Cumberland Pharmaceuticals Inc.


<P align="left" style="font-size: 12pt"><B>About Cumberland Pharmaceuticals</B>


<P align="left" style="font-size: 12pt">Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on
the acquisition, development and commercialization of branded prescription products. The Company&#146;s
primary target markets include hospital acute care and gastroenterology. Cumberland markets
Acetadote<sup>&#174;</sup> for the treatment of acetaminophen poisoning and Kristalose<sup>&#174;,</sup> a
prescription laxative. The Company also recently launched Caldolor<sup>&#174;</sup>, the first
injectable treatment for pain and fever available in the United States. Cumberland is dedicated to
providing innovative products which improve quality of care for patients. For more information on
Cumberland Pharmaceuticals, please visit <U>www.cumberlandpharma.com</U>.


<P align="center" style="font-size: 12pt"># # #



<P align="left" style="font-size: 12pt"><U>Investor Contact:</U>
<BR>
Angela Novak
<BR>
Cumberland Pharmaceuticals
<BR>
615-255-0068
<BR>
<U>investors@cumberlandpharma.com</U>


<P align="left" style="font-size: 12pt"><U>Media Contact:</U>
<BR>
Rebecca Kirkham
<BR>
Lovell Communications
<BR>
615-297-7766
<BR>
<U>lovell@lovell.com</U>



<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>e29814-10111153949103c96e_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 e29814-10111153949103c96e_1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!:`8P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^^BBBB@`H
MIK,J*SLRJJJ69F(5551DLS'@*`,DDX`Y/%?,/Q%_:W^%/P_TN#5[4Z[\0+.Y
MA\-W]O<^`K.RU#2[K0?%$4]U9^)=,\3ZSJ.@^$/$&BVEE"EYJ(\,^(=:UB""
MZLO)T>YDNH4;6C0K8B2A1I3J2?2$6]]KO97V5VKO3<3E%;M+U9]/DX!->0^&
M/C'X<\6_&3XJ_!W1+K1-2U3X0^&OACJOB^XTSQ%9ZEJ.B^(?B5_PFNH6WA#Q
M%H%K`T_AS5+'PIX>\,>+[<:C>FZU;0O'FBW\>G6E@;.^U7^?7]LC_@M]\6?"
M6A^*/#_P+^$_ACP5JC76K:?H_C_QIK<OCF^30Y;"]M+/6K3P7;Z1X<T?0O%]
MM>7%GJEK!JVM?$#PQ:RV#6=_INOVMV^S#_X-K/B7X^^,<?\`P4'^)_Q1\6:O
MXW\?>-/CA\.=9\2^)]<G6:_U*]D\(Z_`@"1I%:V-A96L%OI^DZ1IUO9Z3HNE
M6MEI&D6-EIEE:6D/V,N"<RP?#V:Y_F4:6'IX6&#AA*$:T*U:K6Q./PU&52?L
M92IPI0HRJQY74E4E4J0?)!0;?CU<WIK,\ORVBG*6*J5_:S<6HPA1PU2I9<R4
MG)U.2]DERWM+O_4+1117Q)[(4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`5XM\>_C[\./V;_AWJ/Q(^)>JO::9;S1Z9HFC:>L%SXE\
M9^)[N&XFTKPAX2TR:XM4U+7]46UN9D6>ZLM*TG3+/4O$7B35-$\+Z-K>MZ;[
M23CD\`<DGM7\F?Q&UOX^?\%5?VOM?\2_!?P5?Z[\$/A7JVJ_##X>>.%N=7MO
MA=IGAO3/$&A0>)?'>H>)=8DC\/Q>)/',VIZ+XSO_``UX7TW_`(6#?_#S3O"-
ME)X:\4R>!AJ-?0\.Y+3S;$5JF+Q$,'EF`IPKYABJDXTU&,Y.-'#PG/W8UL1*
M,U!M.T*=648SE&,)<N)Q/L/9PA%U*U:3C3@M7I9SFU_+"+N_-Q6E[K]!/#O[
M1_Q"_:<\0:3JGCNWT_0_#UN;>33OAOH5]>W_`(4L;BT\1VWB+3-2U>>]ALF\
M9^)M)O--\/\`V'Q+JFE:;;6%WH,6L>%?#'@R\U;6X;SO?VH<GPU$3U_LN,G_
M`+\_IR:]+^!7_!/;6_!&@/%X]^*K6>LWWAJUMXX_ACI-DMUX/\52"Z&HZCI7
MBSQSIVMZ9XNT^W26U&CP:U\+]$B%U:2WFJZ?J$-U%IUC]>:Y^R_\(?%=WX4U
M#Q?I?B#Q1?\`A&R2SLWOO&/BG3-+UA_(C@N;SQ7X3\,ZKH/@KQ5<7AC$[0:[
MX;O=.T^=G?1;#2U=D/7BLPRO#YE1J8-REA,(Y1IPHTVKV<6^7VDJ:DIN*YJC
M<I-Q<GSWYI.$:KIOG7OSLVV]5=ZWZV6OZ+6Q_"Q^UT?WFH_6?_T*OUN_X-8^
M/A_^VZ3P#\6_AJ0>QQX6\1YQZXR/SK^C+6_V/_V3?$\8B\3?LP_L]^)$V[<>
M(/@S\.=:R#C.[^TO#ESG=M&<]<#/08_`#_@HKX,\(?LI_M*:/HG[+WA;PY^S
M?HVN_!3P5XCUK2/@)H>F?![3-8\0GQW\5]-.O:I8?#VU\.VFH:T=.LK/3SJM
MW#+?&QM;:T\_[/!%&OTV=<?X/,^&<5D%++\33J8EX.V)J5:7LX?5L30KN].*
M<GS*DXJTE:Z?2S\:.25(YM@LQ=>'+A7B).GRRO-UZ+I))W]WE;N]&G:UU>Z_
MJ)R`<$@$YP,\G')XZ\=Z6OXIM$_;E_:^^'NLOKGA[]HCXI7-XUK/:-!XN\2W
M7Q"T@PRN'8C0?'__``DVB)<AQNCOH]/2^A#2)#<QQS2H_P!W?`?_`(+G?$+0
M-1TKP[^T9\-=)\=:*T6EZ?/XW^'13PQXS@-M!>+J&L:IX7U*YF\)>*=2U68V
M#?9-'O?AKIFG;;R2&&X22WM(/RT^B/Z:Z*\8^"7[07PC_:'\*Q>+OA1XQL/$
ME@([9M1T\K+IWB'09;J2[A@MO$'AZ_6'5M(EGGT_4(K.2[MEM-46RN+O2+J_
ML!'=/[/0`445_(Y_P4*_X*,?\%1/B+_P5AO?^"9O_!/#QEX`^"FK^`?#MC,=
M=UW0O`GB:X^)^K:Q\&/#_P`=-7U/Q'J?Q*\">.-,\*:=X7\-:D=!\.:)X<T2
M"[OM3M]7U?7O$&KVVLZ'H_A'W<@X?Q?$6+Q&&PM?!86&#P.(S'&8O,*\L-A,
M+@\,Z<:M:M5C2K32YZM."Y:<O>FKVCS27DYQG&&R6AAZ^)I8FN\5C*.!P^'P
M=*-;$5\37C4E3ITX3JT8-M4Y-N52.BLKR:B_ZXZ,U_)+_P`*=_X.S?\`H['X
M"_\`A,_LQ_\`T,]>/?"__@H__P`%B?V(O^"F'[+_`.Q[_P`%%OB#\-OCSH/[
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M?[5W[47_``5+^'G[0'Q4E^(/@_\`9N^-/A?P9\&=(?P=\/?"_P#PB'AV_P#B
M)^T5H=W9-?>"O"7AO4O$,DVE^!?"ULU]XIO-;OQ_9AF2Y6>]OY;DP63XO'9=
MF^9T94%A\EI8.KBXU)SC6G''8NG@J*P\8TY0G)5JD74]I4I*,+RBY-<H8O,\
M/@L7EN"JQJNMFM7$4<.X1BX1EAL/+$U'6;G%QBZ<&HN$:C<K)I+4_H:S17X6
M_P#!P7^V)^T=^Q%^Q1X'^+O[+_Q';X8?$+5OVC/!/@74/$`\)>!/&8N?"FK^
M`/BEK.HZ4VD_$/POXLT./[1J7AS1KH7T.FQ:E";,0V]Y%;W%U#/[-_P1Z_X*
M&7/[>G[.%W;?$VPU#PE^U9^SUJUM\)?VH_`/B&TLM%\267Q!TQ+VR7QM+X9@
MM=)NO#NF>.[C1=;DDT&^\.^'V\+>--!\=^!K.UU#3_"%MKVK]<N&LS7#M/BB
M,*53+)8ZI@:CIU&Z^'J4XTW[6O2<(J.'G.K"E"K"I42JSA"HJ;J4^;!9Y@'G
M<\@<ZD,?'"0QD5.FE1JPFY^Y2JJ;<JT8PE4E3E"'[N,I0<U"?+^ME%4M1U&P
MTC3[W5=4O;33M,TVTN+_`%#4;^YAM+&QL;2)Y[J\O+N=XX+:UM8(Y)KB>:1(
MH8D>21U121_&9\&/^"[G[2'[8/\`P6G^%7P2^"?Q%L?#7[#&O?%'5?AUH7@V
MS^'OA1M1^*GA?PQX9\77J_$?Q!XG\:^$KGXE:'?>-]8LXM9T[1M%OO`\6@>$
M[;PUH&J>'SXFMO%FM^(C).&LSS^EFN(P,:4</DV`K9AC<1B)3A2C"E3J550@
MZ=*JYXFM3HUI4:;C&#]E-SJ4TDV9KGF`R>IEU'%RJ.MFF-HX+"TJ,(SJ.=:K
M3I>UFI5*:C0I3JTHU:G,Y1=2'+";;2_M`SCK17R[^V_\0_&'PB_8M_:[^+'P
M\U?_`(1_Q]\+_P!F#X^?$3P/KPL=-U3^Q/&'@KX4^+/$GAG5QIFLV>HZ/J']
MFZUIME>_8=5T^^TV[\C[/?6=S:R2PO\`R`_L&_M#_P#!R7_P44^$GB+XS?L]
M_MD_">+P=X5^(>J_##4U\??#7]G/PYJQ\2:+X9\(>*KLVUI:?LSZ['/I_P#9
M?C71A'=/>K-)<B[C>W584FGZ<CX4Q6>8''9E',\FRO!8"OA\/7K9OB\1A8NK
MB$W3C!T,%BXRNDE[SAJ]%+6V&:<0X?*\9@\`\#F>/Q6.HUJ]&EEV'HUY*GAW
M!57/VN)H6LIQ:MS7U6CMS?W045_)E=_!+_@[&M;2YN8OVP_V=[^6""6:*QL_
M"W[.@N[V2-"R6MLU[^RO96:SW#@11-=W=K:J[AKBY@A#RI]*?\&]/_!3+]IW
M]OKP;^TCX#_:GN?#7B?Q[^SAJWPRC@^)FD:'I?AC6_&EE\3Y_BD9[#Q5X>\+
MV>E>";/4?"=WX`%E8ZEX3T70['5-*OK6*]TI]5L+S7=;Z<=P7BL)E./SC#9U
MP[G&%RQX7Z_#*,PKXG$8:&-K1P^'JSHU\%A?W4JTE"\92:NWRVA-K'"\3X>O
MF&#RVOEF<Y;B,>L0\)+,<'2HT:TL+15>O"%2EB:]YQI7E:R5EO?0_HYHK^9S
M_@X]_P""@'[77[!WA;]DK4OV4/BV?A3??$OQ%\8[+QM./`OPT\<#6[3PKI?P
M[FT*!H?B1X-\86VGBRF\0:I+YFE0V,]P9U6YEFCBB1/!U^#W_!V8PR/VLO@(
M1[>&OV8C^H_9GQ^1(_'(#P/!>(QF4X'.:^>\-Y3A,QGBZ>$AFV88K"XBK+!5
ME1Q'+"GE^(@U"3@VXU)6C4@Y)-V%B>**%#,L9E='*LZS#$8".%EBI9?A,/6I
M4EC*?M:%YU,;1G[\5):TX^]"27,E<_K;HK^20_![_@[,4%C^UA\!B%&2!X8_
M9C)(')``_9GR21Q@<GI7]&?[;WQ$\9_"#]B;]K[XL_#W6#X>^(7PO_9<^/WQ
M#\#Z^;#2]6;0O&7@GX3>*_$GAG6#I>N66IZ)JC:7K>F65Z;#6-.U'2KTP?9M
M0LKRSDF@D\[,.'G@<1E^&HYUD.;5,PK.A!Y3C<1BH8:?/0IQ>,=3!8>5*%25
M=>S<(UG)4ZONIQ7-V8/.?K5+%UZN5YME\,'2]M/^T,-0HNM#DJ3E]7]GBJRG
M*"IVDINFDYT[-J3Y?JBC..3P*_AC_8/_`&@_^#DO_@HE\(O$?QI_9[_;+^$L
M7@WPK\1]7^%NIIX^^&W[./AS6/\`A)M%\,^$/%=V;>QL?V:-<BETXZ7XUT;R
MKHW<;O<_:XC;HL*R2_0'QUTG_@ZD^`'P:^)OQO\`%G[6_P`$=<\)?"7P3XC^
M(GB^Q\)>#OV9;OQ!%X2\(:7<Z[XFU+3[37OV:?#NGWLFCZ'8WVJR6`U2._O8
M;.2UTJVO]3EM;&X^@K^'E?#8V678GBO@NACH5EAYX:KF^-A5A6<HQC3E&64K
MEF^9-*36C5[;'D4>,J.(PL,;0R#B6MA*E'V\*]/`865.=%+F=16Q\I<ME)Z1
MD]-%*ZO_`&.49'K7XS_\$+?V^?BK_P`%#?V)C\5?C;8:2GQ0^&WQ/USX&^+O
M$VB0Q:=8?$6^\*^#_`WBZU\?OX>M+>WTWPQJVM:7X\T^R\1Z1HX&A2^(M*U3
M6/#]EX=T+5M,\(^'OA;_`(*=?\%#?VP_V>O^"S7_``3S_91^#_Q@;PA\`?CG
M<_LKK\4O`(\!?#'7AXG7XC_M4^.?AKXS!\4>)O!>M>,]&_MGP5H^GZ/CP_XB
MTH:<8/[2TH6.KO)?OXE'A+-JN?8_AQO"TLQRZ&.J8AU*TUAW'`4I5JKI5(4:
MDI^T@DZ%Z<.;GCSNFN:WIU>(LOI9/A,\M7J8+&O!JBJ=.+K7QU6%*ES0G4A&
M/+.:]I[^B3<>?1/^H&B@<?Y_.BOF$[I/OJ>\%%%?SL_\%M?^"B'[4WP6^(O[
M,/[#/_!.^74I/VV/VA==A\8;],\)^%/%D^B?"R*37M`TJ'[!\1_"^N?#Z*U\
M8>(M(\4:GK'B[5+N.U^&_A3X5>*]:\5)HFBZQIGB2V]7)<HQ6>YA1R[".C3J
M58U:E3$8JHZ.$PM"A3E6KXG%5U"?L:%&E"4YS<9:*T5*3C%^?F>98?*L'4QF
M)564(2ITX4J%/VN(KUJU2-*CA\/2YH^TKUJDXQIPYHW=VVHQDU_1-17XR?\`
M!#S_`(*/WW_!1']D*UUGXEZ]I.H?M*_!?5E^'GQXMK.PT3P_/K=[(+N]\#_$
MZW\-:3JU\+#2OB!X9A\F_O$TKPMHEU\2O"WQ,L/"?AO3/#&CZ7`O[-UEFF68
MO)\QQ>5XZ"ABL%7E0JJ#;A*UG"I2E)1<Z5:G*%6C.T?:4IPG9*1I@,=A\SP6
M&Q^$ESX?%4HU:3=E))Z.$TG+DJ4Y)TZL+MTZD90E[T6A,CU'YTM?Q>_\%&?^
M"X?[9/[!'_!7?XF_#.PUFT^)O[)?PYC^$T^M_`6^\)^!M,F.B>,?A1X`UWQ#
MJ.C?$VP\)1_$#3]?C\2>(+S4M#?7?$^J^'!?WMOHMWI,NE/:6<']6W[*G[5?
MP3_;.^"7A'X^_`/Q?;>+?`?BRW9>0EKKGAO7;1(1K7A+Q;HWG3W&@^*-!N9E
MMM2TRX>1&5[;4-.N=0T?4--U.]]3-N%,XR;+<JS?%4J<\OSC"T,5AL3AISJT
MZ7UBFJM/#8ERIT_8XGV;4^3WH25_9U*G)4Y>#+N(,NS/&YAE]"I*&,RW$5:%
M>A6C&$ZBI25.6(P]IR]KA_:>YS>[.#Y55IT^>FY_1F<=:*_$'_@OW^UY^T1^
MQ3^P[HOQ@_9D^(9^&7Q&N_CQX#\%W'B(>$_`WC/S/#6M>&_'6HZEIO\`9'Q!
M\,^+-!7[3>:-ILOVQ-+74(/LYCM[J&*>X27]&?V&_B'XQ^+O[%?[(?Q8^(FL
MMXC^('Q/_9C^`WQ#\<^(&L=,TMM<\8>-?A;X6\2>)M8.F:)9:;HVF_VEK6I7
MUZ-/TC3M/TJR$_V73K&TLXH;>/AJY-BZ.2X3/9SH/!XW'8K+Z4(SJ/$JMA:5
M&M4E.FZ2IJFXUHJ,E6E)R3O3BM3IIYIAZF:XC*(JK]:PV#H8VI)PBJ+HXBI4
MI4U":J.3FI4I<T73BK-6D]4?4N:*_DW_`."X'[?7_!1;X"_\%"_V4?V3OV(?
MCE:?#-?VA_A[\,M+T[0-3^'OP;\3Z9J'Q0^)'QK\:?#/1]0U#Q!\1?AQXTU;
M2-/E%KX?MKQ;2Z73[2"VFO4L&N)+AI\F7X._\'9IAE(_:O\`@3(1%(RQQ>&_
MV8HI92J,1%$[?LUQ(DLF-D;230H'*EI8Q\P^AH<#8B>79;F>+X@X6RNCFM"6
M)PE',\SQ6'Q4J,*TJ$ISI0RVM&*52$E>-2<-KRO='DUN*:%/&X_`4,HSW'U,
MMJTZ.*JX#!8>M1C4JT*>(A&,IXRE*3]G5BW[B=T[*S1_6]1G'6OXP+S_`(*L
M?\%O_P#@E_K7PUOO^"I?[/>@?%7]GWQA\0K[1-7^+.@:5\-+7QO<6ITYO(T+
MPKXO^!OB:R^$&@:W!#!<^,/#/@_XH?#_`$3Q1\1=,T+Q1I%MK^@P6^H>)_"?
M]-_Q&_:MTK5_V3_`G[1?[/&M>#_%^E_&_6OV=/"WPI\7>)H]3@\):>/VFOBY
M\-_@_P"'?'?B'PW+?^$_$>JQ>`[CXE6_BW5_A9-K7@/Q;XIN_#UQ\-SXC\">
M(M5&M:/YV:\)YGE,L!*57+\PP695GA\%FF58V&-RZM6C*$:E'ZQ",94ZM/G3
ME3JTX2:4^13=.HH=67<18#,5BH0IXS"8O!0]KBLOS##3PF-I4VFXU/95/=J4
MYV:C4ISG&]KM*4'+[0R#T-%?B-_P3W_X*&?&C]H[4?A1KGQ#\-:"/`7QUN;7
MPQI^F:/+XMUKQ[\,/BSK_P"S\O[6MEI_B:X\1?"3X");_"6#X-W6FZ7'J%M\
M/O%>BZ9KGB_X%ZAX/_:&_:+L/C?K<WP8_;FO)S/+,7E&*>$QBI^U45.]*?/!
MQ;E%VE:+O"<)PE>,7S1=ERN+?J8/&4<=1]M1YN3F4;37+)-PA45UYPJ1DO6U
M[II>??%GP=K'Q#^%WQ'\`^'?&&I?#W7_`!KX$\6^%-#\?:-:I>ZQX(UCQ!H-
M]I6F>+M)M)+BT2YU/PY?7<&LV$#75L);JRB7[1#_`*Q8?A'\(OAQ\"/ASX3^
M$WPE\)Z9X*^'_@C28M&\.>'M*20PVEHDT]U/<7=Y<R3ZAJ^L:IJ%U>ZOKWB#
M6+N_UWQ%KNH:EKNO:CJ.L:C?7UQU/BJSUS4?#/B+3_#.KQ:!XCOM$U6ST#79
M[-=0AT;6;FQGATS59;!PR7L>GWKPW;VKJ4N%B,3`JQ%>1?"CX_>$?B(UOX>O
M[M?#WC^.VLS<^&M8M+O0+G5IIK/4+R:7PY8:P4O[F2WATC5+G5O#TF_Q)X6B
MM&/B"RM[.?3=2U/D]M55%X=3DJ,JBK2IIVC.JH\D9S2^.4(N4:;E?V:G4Y+>
MTGS=')'G]I9<_+R<W50OS.*?12DDY)?$XQO?EC;WNBBBLB@K\,O^"E_['G[1
M_P`?_C[X<\;?"'X;MXP\,V7P<\+^$[K4E\7^`M`,.OZ;XV^)&L7EB;/Q3XIT
M._<0Z=K^DW'VJ*U>SD-UY,5P\\%S'#^YM%`'\>VM?\$O/VZW2>6/X%32K%&[
ME8OB-\))9'&"V(HH_'K22O@<1QJSEB$52Y"U\4^,_P!E;]IKP'-J>K>,?V?/
MC1X=T/PQ<R?V[XDU+X:>,(?"VG0VDGE3WDOB@:0WA]]-#,GEZG#J4FGSI)')
M!<R1R(S?WOTFU<D[1DE23@9)7[I)[E?X?3M0!_&Y^ROXZ\8?#[7-/\1>"/$F
MJ>&=:ACB@%]I<ZJ9;1[B"XDLKVUG2>PU/3IKBTMIKC3-3M;S3;J2VA^U6DPC
M4#^J/]G'XU/\:O`<.K:MI]GI'B[2#!8^)].TZY%QILLTD9:RUS24EN;G4+32
MM<CBGEAT[5'DOM)O[74]'>^UJ#3[?7]7W?B%^SW\%OBG<2:AXY^''AG6-:E^
MP+)XDALO[(\5O%IC,]A:OXKT5].\126%L7<+ILFIMI\B.\4UK)$[(?G7PY\"
M[K]FWQ7IWCC1?$UMJ?@:P>RT?6KWQ//I.CZMIOA35UTZPUYO$.N)H\MG>VEM
MJT$'BZ,Z%8>%Q=7NFZ%H^H1VVEV6I:Y,`?=U?QG>'/\`E;]\<?\`8N0?^N[_
M``E7]F/^?7]1Q^5?PJ?MY_&O5_\`@FI_P<6>(_VZ_C9\(/B7JWP1\5>&=+F\
M`:KX9TRQ\OX@PO\`LC^$_@QK9\+:MK-_I7A^[O/"GC1)[;Q+I%QJUMJVF64=
MMJ$EFUIJVBRZC^C>'-*IB:_%V!H1]IB\?P3G.$P=#FA&>(Q,\3ETXT:?/**<
MW"$YVO\`#"<GI%GQ7&M2&'I<.8NM+DPV#XIRS$XJKRRE&C0A2Q:E5FH1E)03
ME%-VWDENT?W5UX?XU_9P_9O^(_Q&\*?%SXB_`CX)>._BWX#.@_\`"#_$[QK\
M+_`?BCXC>#&\-:Y<>)?#)\*>--=T*^\3>'6T#Q)>7>O:$=(U*S.E:W=7&JZ?
M]GU">2X;^;+_`(BV/V.O^C;_`-I?_P`!_A;_`//&K\^YO^"B/QR_X*R?\%BO
MV)_$_P"Q-I?[47@CX-?#R]^`=U\>?AQ/XRN?#?A`>$?A=\>/$/Q!^*7Q`^(&
MF^$_&-SX"_X1J[\!:YH_A>*3Q/=#4O%VM6^E>`M-L-5UG5_"^C:I&"\.>*J/
MUFOF5&KD&#PN`Q>(KYC6JT72C3HT7*5"7L,4I_[1&]-7]QMI23NDZQ7&G#]1
M4*."JT\XQ.(Q>%P]+!4X5%.4JM:,553JX>4;4;^T>FRWBKM?U<_\%8_^49O[
M=O\`V:W\9/\`U"M6KY:_X-V_^4/'[(?U^/W_`*U#\;*^WO\`@HS\/O$WQ5_8
M&_;+^'7@O1M5\1^,?%_[,WQJT;PGX<T*PGU36_$?B6?X?:^V@^'M(TZU26YO
M=3UW54M-)L;:"-Y9;J\B1%9B`?Y*?^":_P#P<$?L^_\`!/3]BWX0?L=?%OX`
M?M#:I\3/@K??%?2O&D^DZ3X)TVQMM8\2_&KXC>.?[+6Q\2^,]%U^TO='LO%%
MII>KVNJZ1IUU:ZS9ZA:^0T4,5Q/T9'E&8Y_P'C\MR?#2QV.H<6X+&U<-3J48
M58X5Y/BZ'M[5:E-.'M9*G=/XM.C.?-LQP>4<88+&YE76%PE3A[&86&(G"I*G
M+$/,,'5]BG"$_?\`9P<[6^'6Y_=#-_JI?^N;_P#H)K^3[_@W4_Y/6_X+??\`
M9R/@O_U;7[7%3M_P=K?L<LK*?V;_`-I@!@5)%O\`"W(!&#C/Q&QG%8W_``;(
MR^(_B!\5O^"I7[2J^!O&/A?X7_M#?&/X?^*_AKK?B;1+JPL?$`/C?]HWQ+KV
MD:5K")-H>MZIX.M?&WAFU\51:'J>I0Z3>ZO8133[;RV:;LPW#F=\.<'<;RSO
M`3RY8W#Y#2PGMJV&<L35I9YA:U2G1C3K3E.4*47.2MI'5M(YL7G65YWQ'PI3
MRK%PQDL-BLTJXCV<:B5&G+*ZT(SJ.I"%HRFU"+U3DU'=H]M_X.M_^4<'PV_[
M.Z^&_P#ZJWXVU\]?\%+?@Y\1O^"3/[9G@#_@LK^ROX836_A'\2KZV\`_MP?"
M73-%-GIS0^.;O0[76/&8U#1I;.+2HOBQK5GI.I-KNHP6MMH7[1FE>%/$OB"Z
M\<Q?%"^\)0?0G_!UN1_P[A^&PSS_`,-=?#<X_P"Z6_&W_$?F*_H:\9_#;P)\
M:/A#XE^%?Q(T"S\7?#WXD^!]8\$^,?#]S-<PV^N>%_%&D3Z/K>G"^TZXM=1L
MC>Z==SPQZAI=[9ZC92,EWI][:W<,-Q'E@,]>2<+\)U:E/ZWEN*S/BS!9QE[E
M[F.RZO3X?5>B[-<M:/*JV&J)J5+$TJ<T[1:>F+RK^U.).((0F\-C*&79!BLL
MQJC>6$QU">9^QJQNK2IN\J6(IN\:M"I4IRU::_FV_P""MW_!0G_AM#PE^S3_
M`,$X/^"</C[PY\0OB+_P48T+3=9\5^/-)UKQCHMK\/?V==4"ZO=P^)CI.EV^
MH:*?&&BZ%XVN/BUX6U1+[QCX3^$_@3XA^%O%OPNN+WQ_X="?%WCK]ECX<_L5
M?\%X_P#@CG^S+\*X[L^$OA=^RUX0T[^T]0GN;C5/$WB/5/'O[8NO^,_&&JO=
MW-V\.H>+_%NJZUXCN--M9DTC1#J*Z'X>L]-\/Z;I>FVG[;_\$G_^"+?PN_X)
MA>+OCU\0=/\`'.I_%7QS\3M<O?"_@3Q%K.G:=87O@/X!66K+K&A>![I[*PM/
M[5\8:_J4.F:I\3/$5G_9GAOQ!>>%_!J^'O"'AA=&U&77?S@_;^_Y6=_^"97O
M^SYX0QGO_P`5C^UTO'K@\<?C7JY+F>54ZV9\.\.U:M7),%POQ1C*F+KP=&OF
MV9XC*JB^LUJ3C3<8X+#RA@,+3=.*2A5K13^L7.#,L!CZE/+LZSFC3IYKB<_X
M<P\,+1J*O1RW`T,UP[]E1J1NG+%5>?%XFIS._/1I-J-!'[^_\%*?^4='[?7_
M`&97^U-_ZHWQU7\77_!$3XT?\%HOAU^RS\0=$_X)R_LE_`'X\?!:[^/OB?5/
M%/C#XK>(M!TG7M-^*$GPZ^%5GK7ANRMM5_:6^#DSZ1:^$[/P/JD$Z^%K^)[W
M5M0C37[EX9M.TS^T;_@I."W_``3I_;Y4`DM^Q9^U*`!U)/P-\=8`'<GTK^+[
M_@B!_P`%N_V5/^":G[*WQ!^!_P`<_A]^T'XM\5^+/V@/%/Q6TW4?A-X5^'&N
M>'H?#NN?#GX4>$;6SO;OQA\5_`FI1ZS'J7@75IY[>#2;JQ6QN=.EBU*6>6YM
M;3#@2EBZ_!_$M/`Y+A.(,2\VRJ4<MQM.I5H5(JG+FJ.G2Q.%FW3^*+59+1W4
ME=#XOGAJ7$O#]3&9IBLFH++<TC+'81J-:$W/".-+FEA\3%*I9W3IW;4;-'[%
M2_M4?\'4$44DK_\`!.#]C9EC1G81>,?",TF%!)\N&']NUI9G&/DC1'9VPHC<
MG:?*?^#4?P[\(K'X>?MD>)-&^(/CC5_VA-=\9?"73_CU\,_%GP]B\$:9\/+;
M1HOBG=>`[_POJ=KK&N6OBZV\5ZGK7Q$L]4N+EO"NO:-J/A)M-U+X?:'IIT#Q
M'XR]1U?_`(.SOV`8=*U*;0O@5^V'J&MQ6-U)I%AJ_@WX+:/I5[J:0.UC9ZEJ
M]G\=]<N]+L;FZ$4%UJ-KHNL7%E`[W,.EZA)$MI-Y=_P;`?#_`.-VO>(/V]/V
MNOB9\--?\`^"_P!ISQQ\/O$7P_U._P!%GT3PWXUU-/$'QI\3^.+OP-%=QVUQ
MJ7A7PO=^,='T6UUZULFT&\OKV_T;3=4O-3\.^(K/3_1S#"YGAN".+?[6X:RO
M@]3_`+$^JK+J;PTLZJ4\PA*I@JM+%8W'5*T:,']:A+#^PG3G#]Y.=)5('+@*
M^!K<4<.O+L\S#B5P_M18AXZ]1992G@5'ZU1G2PN#ITIU9)8>2K^UC4A/DA&%
M11D>;?\`!WU_R)'["'_8U_M">_\`S!_A#VY_D:^F(OVK?^#ISRXS%_P3>_8Y
MV;%V[O%GA8/M_P!H/^W8&#=<@CKZ5\S_`/!WS_R)'["'!./%?[0A./3^R/A"
M/YD#/09&>HKZFB_X.Q_^"=B(%/P6_;3)4`?\D\^!N.,]/^,BAGO_`/JQEY;A
M\TQ'`?"*RSA3+>*.3$\2>W684*];ZCS8_#^R]E[#'8)Q^LVG[3F=1/ZO3LH6
M?-GC:^`P_&/$SQ_$.89`JE#(_8_4IP@L9R8.?M%4Y\'B[_5^:');D_C3OS.S
MA^[G[%/BS]JKQQ^S3\//$_[;/PV\&_"+]IG4IO&8^(_P]^']W!?>$=`2R\>>
M)[#P:=)N[;QW\3+:;^U?`5KX7UJ_,'C;6HTU/4;R,?V<4.DV/'_\%+?^4<G[
M?W_9E'[5'_JB_'=?BN?^#LK_`()UX/\`Q9;]M/\`\-Y\#/\`Z(NOVD_X*3R+
M-_P3@_;[EC8/'+^Q-^U,\;+R&1_@5XZ92".""#D$$@YX-?GN(R3.,HS[*L1F
MV4/)X9CF].KA:"CR8:"AC*%2I1PR=6M.-'#QKTX0C4J2FJ;A><W>1]KA\WRO
M,\HQ]'+<Q>92P66RIUZTE/VTF\+5A"K6E*E2C*K6=*<YN$4G/F:C%61_%M_P
M10_X*L_&+]A;]ESX@_"7X>_\$^_CA^U?H_B3]H'Q5\1;CXA?#.\\4P:'HVHZ
MK\.?A7X:G\&W4>A_";QY;'5M.MO"-GK<[/JUO/\`8O$%B'TZ*-8[FZ^QOBO_
M`,''7Q!_;A^`'[1G[.'P7_X)I_%[Q;K_`,5O@O\`$3X3ZCJ7@7XAZW\2+CP1
M%\4_"FM^`X/$NJ>'_"OP,N;RZ33;C5I+FTTF>YTA=;N[3^RDU;39)3=P?;G_
M``:<%6_X)W?&M201_P`-I?$+C()P?@=^SJ1QSP2#U&#CUK(_X*W_`/!-OXM_
ML[?%>]_X*Y_\$QI[SP!\?_`;7GBO]H[X1^%;&5O#_P`9O#K75M?^,?'=MX6L
MA#::QX@U>.-[WXQ>"W$6F_$JSM3\1=-.E?%G1M9U#XD?IN88O@S%<>9U@<RR
M*A1S-9@_J&:U\ZS.E@L1FM/V#H4\?2HS5/"4<1-1I*K3C5A2J\L9TI0FW3^&
MP6&XGH<(Y3BL#F]:I@/J-)8S+J.5Y?/%T<!4I6K2PDZM-SKU:/O2]G5E"=2F
MVX3=1*,_HG_@VG_9O^.7[-7_``3\\5Z)\>_AGXN^$OB;XC?M*?$3XDZ!X.\?
M:#JGA3QG;>$SX*^&'P\M[[Q#X4UVUL->\-W%_P"(/A[XBET[3]:L+.[OM"&D
M^(;6.;1];TNZN/R^_P""T7_*Q%_P29_Z^_V(/_6Y/B97]`/_``2N_P""J/P9
M_P""F?P<7Q#X;:S\$_'#P78V$/QC^#-W?1R:GX<U&X14'B7PQYL[7>O?#W6;
MKS%TG7#&MQ8W0DT76XK;4H4:[_FG_P"#AKXMZ-\`_P#@MA^P#\=_$.G:EK/A
M_P""?PT_9C^+6O:1HJVKZQJNC_#?]K7XQ^,=5TS21>W-G9?VI?6.CSVUA]LN
M[6U^URPBXN(8B\B^+PX\UQGB7GLLTP3P.:XK!<0.K@-$J5:K@9>QH4I2DU4C
M*'(J57G<:R:J1ER237I9XLOPO`F6+`8EXG+\-B,C5/$M7E.E2QM#GG4C%>Y.
M+352GRQ=*2=.24HR/[JJ*_E"_P"(MC]CK_HV_P#:7_\``?X6_P#SQ1_*OJO]
MB/\`X.)?V;/VY?VH/A?^RQ\/_@E\;_"/B[XIOXQ32O$7C./P%%X;TT>#/`'B
MOXA7YU!M$\9ZQJ9:[TWPG>6%DMM83;K^ZM?.:*W\V5/C,5P!QA@<+7QF*R/$
MT<-A*%3$8BJZN$<:5&C!U*M1J.(<FH0C*348N5EHF]#ZJAQAPUB:]'#4,VH5
M:^(K4Z%&G&&(O4JU9JG3@G*BE><Y**;:6NK2/W1^*_Q.\'?!7X9_$#XN_$/5
MTT'P'\,/!?B;X@>--:>UOK_^RO"OA#2+K7-?U%-/TJVO=5U&2STVSN)HM.TN
MQO=2OY52TL+2XNYH89/Y>/\`@A=\/?$/[:W[5_[5_P#P6D_:(T;3]*UOXF^,
M=;^%_P"S-X8\00:9--X.\(:98Z?H6LZWX?O+GP%X;LM8B\&^!=,\'_`7PO\`
M%+PC>6.H^)+K2?CWIOC;33K6IWD\VS_P<2?M!>/OCMXM_9R_X(\?LV&WUCXM
M_M2^,_!7B;XN&.UU'4=/\.^`[3Q0DW@#3/%JZ7X0\4W^E>&1XI\/WOQB\?:_
MH,MMXB\#>#/A'9ZOJ6GWOA/Q3<QW?1K_`,&FO_!/DJOF?&G]LIG"@,T?Q&^"
M2(3R3L0_LX.57))"[VQGDD\U]#DN$R?)>%:]3.LSQ&4YAQC2]GA*N$R]9EB:
M/#V%Q%/V\726.PDJ*S?%QC>4FXU<)A(\CE[2HH^+FF)S3,>(*,,KR^CF>"X<
MGSXFGB,;]1I5,XQ%%^Q<*CPV(]K++L--R:Y+0KXE7<:E'W?EG]I3Q!'_`,$4
M/^"WFA?M2V.I"T_8L_X*)MKMQ\:+:+4-5U/3_"WC#5M<TRX^+_B.:PBU_P`8
MZYJ&I>!?B+KN@?':WU:#POIT?_"'_$WQO\'_`(::/%!87\L7]E\;B1%<!E##
M.UQM<>S*>58="#R#P>:_D-_:._X-1_V:-&^!'Q7UC]F?XJ_M.:]\?=$\$:YK
MOPG\,^/_`!A\&M<\(^,/&6BVIU/2_!&KV]M\+_A:=/'C9K1_"=CXDNO'6BZ;
MX1U+6;3Q5J\>L:7HUYH6I_:G_!N!^WL_[5?[%\'P%\=:@TOQJ_8]@\/?#/5$
MGC\JXUWX/365Q;?!OQ$Z6^A:/ID%UI&EZ+K'PPU&PM[S7]=8_#RP\8^+M134
M?'=HDM<58?*\[X?R_/<FQ]?-,3P]3PF29]7Q&`>78FKA9*7]D9C5P[KXA3Y(
M1>7UL1[>M4KU(493<'%P2X=KYAEF<8O*<SP-/+J&;RQ&;931I8M8RE1K1=/^
MTL'3K*C048RG-8VE15*G"BIUHKF<N:7Y??$'PIX:\>_\':=SX!\::'I?BGP5
MXZ\$^(?!_C/PKKMC;ZIH'BCPMX@_X)K>(].UOP]KVDWD<UEJNCZK8S2VM_IU
M[#-:W4+M'-$ZG%,^/_[/G[3G_!N?^TM?_M=?L?V'B7XK_P#!-WXJ>(-(L?C)
M\']6UC4]5B^&SZKJHM--\*>+M2D6YN-/@M+JZ73_`((?'>]AO[_3[[4+3X6?
M%*ZUS4M8LK[XO]%J3*?^#P'PZP((_LZX&>V?^'<NO)CZ[_EQ_>XZU_9'XK\*
M>&/'7ACQ#X+\:^'M%\6^$/%NB:IX:\4^%O$FE6.N>'O$?A[6[&?3=9T/7-&U
M."YT[5=)U;3KFXL-2TV^MY[.^LYYK:YADAD=#VYQQ%/):G"E&M1IYEDF8<`\
M.T<WRBM+_9\92C/&6J0E%.5#'89VJ8;$T^6K2J12O9M'+EF21S.'$-:C5E@<
MTP?%V;5<NS*E%.KAJKI8)3C.+:5?"5U%4\3AIWA4ALE-*2_DZ_X+W?M:?`_]
MMC_@C)\,OC]\`/%L7BCP1XE_:?\`AI:75M<)#9>)?!_B6Q\%_$@ZSX+\;:$E
MS=3>'O%>B//";S3IIIH+NRN=/UW1;W5O#>L:-K.H?T&?\$T_^4<_[`W_`&9=
M^R[_`.J1\#U_%-_P6,_X)3?%S_@FEX8^-GB?]F^VU#QY_P`$\OVA]7\%/XF\
M-ZO<^(_$.L?LN_$/0/&.G:MX&N]4E75$;4-(+WFO_#3X9?%WQ/'KS6GAOXC^
M)?A9X]5?'^M^`O'OC[^UC_@FD0?^"<W[`V"#_P`87?LNCCG_`)HCX'_EW]#Q
MUKFXMPN583@C(HY+C_K^6U^(<UQ6%G4Y8XO#TZ^"P7^R8^G'2GC,-*$J=2UH
M58J%>FE3JQ2UX=Q./Q7%F:SS/!O!XZCD67X;%1A>6&JU:6,Q7^T8.J_XF&KT
MY0JPO[U.4IT9WE2<G_-'_P`%K/\`E8`_X)$_]AS]CW_UM#Q17]FHZ#Z#^5?P
MZ_\`!Q%\6M$^`7_!9'_@G;\=O$NG:KK'ASX+>!_@!\6->TG0DM)-:U31_AS^
MU%X^\8:GIFD+?W5E8MJ=]9:1+;6(O+RUM?M,T1N+B&+=(OV)=_\`!VW^R+%:
MS/8?LS?M'75VD>8+:\D^&6GVTKC&$GO8?&^IRVR8R3(EA=-D8\KG<O3FW"^?
M\0\-<!U,FRVKCX8?(\52K2I5,/!4ZDLRQ$E"7MJU.TG'7M9[DX'/LHR;/^+Z
M>9XVGA)ULTP52E&I"JW4@LIPD7*/LZ<TTI1:]4?MI_P5N\#>#OB%_P`$S?VY
M="\<:;;:IHUA^S/\6?&]E;W4TL$<7B_X8>#]5^)/P\U%7AEA+W&C^/O"OAO5
MK*"1GAGN[.&"2*993$_Y:_\`!MS$/VAO^"1%[\'?C7X0TKQ!\,O!WQR^+GPU
M\(:3J>CM#;ZUX*OIO"GQ>DU?[6X62ZU;2OBI\0O&<^B^)]+EM]0T'4M&TTZ9
M>6FL>'X[J+\P?VD?^"C/_!1O_@NO\-](_9'_`&./V'O%?P?^"7Q-\9)I/Q9^
M,6MZOK?B[P9K.E>&KW2_%>CZ3XF^+]U\//!_@7X4^'M'FTK_`(23Q=H>FS^*
M_'OC>XLM`\)^$9[A;_4?!OCW^M3_`()__LD:-^PM^R!\$?V6=$\0:AXKB^%W
MAW4DU?Q-J4=O!/KOBWQAXEUKQ[XVU&UL[:&*/3M&F\8^*-='AS2I9-0O-(\/
M+I6EW^LZW?6ESJ][YF:8:MPMP3'(\SKT:6?8WB:AG%#+L/BZ.(Q&5X?"X'ZN
M\97GA:M6GAL17G.-.G34U5E!<ZE>E5A2Z\!7IY_Q2\WP%*K/*<+D=;+*N-K8
M>I0HXZO7Q<*ZP]&.)A3E7H4J2G-SC"5/GF[-*47/I/@=^QI^S]^SOKW_``E7
MPV\-^+YO$]OX'TOX8Z-XD^)?Q=^,'QOU_P`(_#?29;.XA\`>`M:^-7COX@:G
M\/\`P;?WFF:-J'B#PUX*NM!T?Q3J/A[PQ?\`B6TU:[\+^'9M,^HZ**_-ZM:M
MB)^TKU:M:IRQA[2M4E4GR07+"//-RERQ6D5>R6Q]Q3ITZ4>6E3A2C=OEIPC"
M-W:\FHI)R=E=[NRN]`K\E?V[_@-<Z1;ZM\3?#=E/=^'=<NYIO%.GP:?9+:Z!
MJE]'!'<:BHT^U@<Z9XDO3<7NIW&IK<3#Q'>W;2ZA)!J^G6%C^M55[JUMKZVG
MLKVWAN[.ZBDM[JUN8TFM[FWE4I+!<0R!HYH)D+1S0R*T<L;-'(K(S*<BS^42
MX_X*$_M8?!&>!O#WQ/N_%&DV6HRZE/X?^(]E;>-[/4]R11OIUWK>J#_A-;/2
MBD,?EV.A>*]'CMFWR6I@>65G].^''_!>7XNP'4(_BA\!_ASXL=SC3'\!>(_$
MWPY6T4,`WV]/$*?%,ZBY'W6MY-+1223&XP%^M/VU_P#@D_)\0AX@\=?LUZI8
M:/KEZUYJ=Y\)_$-Q#I_AFXF%A-<36_@77A`6T"YU'4H(UL_#WB%V\,V]WK%S
M]F\0>$O#^G66E1?S@_$GX"?&CX!^(CX>^,GPS\7?#S4IKK4[33Y/$.DSP:1K
MLFDRVR:E+X8\10B?P]XKL;-KRT$NI^&]4U73L75LRW3+/$6`/Z!="_X+FVE_
M?1QZK^S->:?I[!"]SI_Q@MM5NUW,0VVQN/AAHT3[5"D?\3"/.3GJ`GZ?_LD_
MM?>%/VN-!\5ZWX8\)^(/"G_"'WND:?J5MKMQIUUY]SJUI<W2_89K"5O,A@^R
M2HTD\-L[[HV$2[F5/XN-&^^G^ZG\Z_I+_P""*O\`R(?QR_[&GP=_Z:=:H`_;
M>BCK2%@H))P!U)X`]\GL.I/0#D\4KKNOO`6N(^)FK>`-!^'/CW6_BO<Z!9_"
M_2/!?BG4_B-=^*XX)?"]MX$L-!U"[\7W'B2.ZCEM7T&'P[#J4FL)=1O;OIZW
M"3(\;,I\3^*_[9G[./P?T[4;SQ'\2='UC4--U#7-$G\.>"3+XUUZ'Q)X?M;J
MXU#PWJEMX<34+7PKJPFM6TL-XTO?#6EP:O/:Z=?ZG937"5^.,/[87Q<_X*5_
MM>?"W]G3X:^&?^%??LP>#_%7ASXP_&6+6K;0]>\5^-O!7PH\5VOBB/1O'=M<
M:M;Z+!X2\;>*(_`?@2Z\&>&%\2W]C<ZQ=^(M5UCQ3X;@OM+TKZ#+>'L?CH5<
M75I3PF682E/$8S'8A>RA"A27-.-!32EB,14_AT*=*$^:K*$963;.:OBH4E&,
M6JE:I)0ITXN]Y2DHWE;X80;4IMNZBFTFT?T7KC:NW.W:-N00<8XR"`0<=B`1
MW%(44YR,YP#GG(!RO7T))'H2?6E10JJHZ*H49)/```Y))/U))/<U^0'_``4R
M_:2\7_!#XY_L$>!8?VD_&'[+_P`(/C=XZ^/6B_&CX@^`_!OPL\7^*UTWP-\$
MM9\:^!K;2E^*GPA^->E:9Y_CFRTG3[^>Q\&7-Q<:9J5Y%+-:[8-0L/-R_`5L
MSQ<,%0<%6G2Q59.<:LX\N#PM;&55&-"G6K3G*E0G&E"G3G*=1P@E[UT8O%PP
M=#ZQ4C.454H4^6#IQDY5ZU.A#WJTZ5.*4ZD7*4YQ48IM[6/U]\J/^XOY4>5'
MQ\B\9P=J@\@J>@'4$@XZC@\5^4O[#/QV^-OQ!_:$^-/@&V^('Q5_:;_9'TKX
M<?#WX@?#G]J#XT?`N#X">+K'XD^)=5\1>&?$OP1T2?1_@]\"?`?Q]\&6^F^#
MH_B7IGQ.^'OP[M(_"$OBT^"_%/B'Q5)>^'KO3OK?]N;XA^,?A%^Q7^UW\5_A
MYK!\.^/_`(8_LR?'CXA^!M?%AIFJ'0_&'@KX6^*?$OAG6!IFMV6I:-J)TS6]
M,L;T6&K:=?Z9>>1]GO[*ZM9)8)-,1E=;#YA1RZI.C.M6^JJ,E[10C];4'3C5
MA6HT\11G'GC[6E5H0JP6O(XRBY9TL=3JX.>-4*L:=)5YR@_9RG_L[FI\DJ=2
M=&I=TWR3IU90EI[Z::7U.>>#T-,,<9ZHI_"ORO\`V5_^"C_PI\6_LL_LZ^*?
MBSX@^,NM?%'Q/\`_A)XB^).N:?\`LF_M(RZ9J_CW7/A[X?U/QAJUC>^"?@>/
M!,MA?^(;K4;RVN?"+CPLUO,DN@L-)-H:^L/V'?B)XP^+W[%?[(7Q8^(6L?\`
M"0^/OB?^S!\`_B'XXU\6&EZ5_;GB_P`:_"KPIXE\2ZO_`&7H=EINBZ9_:6LZ
MG>WO]GZ/IVGZ79>?]FT^QM+2.&".L9D^.P,*]7%494HX?%QP5YTZU/VM24:\
M^:@ZE*"G22P\N9WC)<]+W/>;BL/F.$Q52E3P]6-657#RQ-Z52G45.$)48\M7
MDJ2<:EZ\>56:]VI[RM[WT_Y4?]Q?RI1&BD$*!@8&`!@<''`Z9&<=,\]:^>/V
MK_VA]'_98^`7Q!^-FJ>'M<\:7WAFPL=,\%?#[POIVNZMXH^)WQ2\8ZM8^#?A
M+\+/#-AX;T'Q-K$GB#XF_$O7O"O@32;FWT+4+?3+SQ!%JVJ1Q:38WUQ#\D?L
M3_&+]ISPG\5/%G['O[='BOPUXV_:"3X:^&/VC?AO\2O`G@U_#'@/XC?#7Q'%
MX>\.?%KP;HYT[2;+1/[6_9P^-U]<^"(Y;Q=(\2^)OA+XW^"7C#7=(G\3:OXM
MU`S1RS$5\!B,P@Z7LL//E5.4I>WKQ@Z2Q53#4U!JI#!+$8:6+]^,Z=/$0JQA
M.G3Q$J-5,?1HXNC@Y>T]I64??BDZ5*4_:?5X5I<RE"6)]C7C0M&492HRIRE"
M<Z,:OZ?LBM]X9&<X.,9'ZC\#ST/%*JA0%48`X`'``[`#L!T'M0?ZC^8K\#OB
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M-&LVGBD>(;'5/`<GPLUW4=#TWQWXITGX>^*_$_PQF\1^*Y_AWXM\;_#:P\'^
M,_%O@B;6GD\*^)=?U70CIVB_8/['L?`_^"G_`,1?VL?`?A']F?2_V,/&&A^%
M?C7\1OVE+OPQ8Z9XG\*>%?%OAKXFZ=X,_9@_::^.=K\&_$,7BJXTR/PWHGQ3
M\6?"'PMX.U7QMH'B+PIXG\)6&ISZQI7B*T%O<6]W5#*JU?-I92L1A*=6%?$4
M)XJ=5O!16&C4G6K>WA"3>'4*4Y*HH6Y5S-)7LZN/IT\#3Q[H8F<*D*%2&'C2
M7UKFKN"IT_93G!*JI3491Y[7NDY*S?Z<LJN-K`,IX(/(((((.>H()SZ]Z;Y4
M?]Q?RK\QOB[^WI'XQ_8<^%OQL_94C&K?&3]L)_"/PC_9?\,>([&[N[CPS\<_
MB3'J>EZK_P`+0L_"FB?$*ST6W_9A30OB'X]^/-C<6]_I>BZ5\&?'N@3:FM['
M;R2='_P2;^,GQ;^/O[!OPA^*/QU\<2?$GXJ:MXI^/OA_Q/XXE\-^%_"$OB&/
MX>_M%_%GX<^'[J3PWX,TC0O#6ER0>%_">BV3Q:;I=OYK6IN;R2[OY[J\N*JY
M-C</EU;,JZA1IT,SAE53#U'..+^LRIXF<IJGR.'L:4L+6HSJ.JFZT94Z<9^S
MK.G-+,\+5QE'!47.I.M@)9A"M!1>'5&-3#TU!SYU+VTUB*56,(PDE2Y9U)0Y
MZ2J?HOY48_@7_OD'I]:545,E5`+8W''+8&!N/4X'`ST[5Y+\>?C=\//V;O@W
M\2?CM\5];A\/_#[X5^$-9\9^)]1EEMHYVL-'MFE33=+ANI[=-1U_6[QK71/#
M>C0RB]UWQ!J.F:+IZ2WU_;Q/^:7[&?[1O[6/A#XXZ/\`!7]OC4=&L?$/[87@
M'Q%^TS^R[H]KHW@O0'^$%YHVIS:C\5_V%=4U?3+KP_KGQ/\`&?P'^'&O?##Q
MIH_C2Y^'RZOXPLYOC1=WOB76].^'UO<KEALLQ&*PF*QM.5%0PR=J<YN.(Q2I
MP]KB?JL%%^V6!PZ6)QEY15"@XU-6TC:MC:5#$4,--5'*NU><4G2H<\U3HO$2
M<DX?6*S]AA[1DZM52A'X96_8=D5\%@#CU`/7'J/;MBF^5%_<7\JD/'-?F1:>
M+OVC_P!K?]H?]H_P%\-_CA<?LT_L[?LM?$+PO\'[CQA\*_"/PY\9?'SXL_&Z
M3X5>&OB;\0+2ZU/XZ>`OB-\,/A]\)O!VB?%KP'H-MI%I\)?%?C7QEXNTC6M:
ML_B/X4\-VR^'M<RPF#EBOK$O:TL/1PU'V^)Q%=U/9TX.I2H07+1IU:U2=2M5
MI4X4Z5*<O>=22C2IU:D*Q&)6']C'V=2K4KU?94:5+D4YS5.=63O4G3A&,*=*
M<Y2E-*T5&/-4E"$OTR$<1Y"+^5/*KM*X^4C&.V,8QBOF+X-?![X]_#'QYXBO
M/&G[67C']H/X5:UX3TFWTKPI\7/A3\&-$^(WA+Q]8:M?R:AX@T3XD_`?PC\%
M?"UWX*USP_=6FGWO@?Q)\(=?U^WUW3+;7M,^(^GV$VH^&M0^A/$MS-9>'-?O
M+9_+N+31M4N;>0JCB.:"RGEB<I(KQOLD56VNK(V,,""16=6C&%;V-'$4L3%N
M"C5I1KPI.4U%VMB*-&K>#ER3?LN5RB^24XVD]*52<Z:G.E5HRUO3J.DYKE;2
M?[JK5AJE>/OW46N90ES16RJ*N=HQGC\`2<?F3^9]32D`C!&1QQ]#G^E?SY?L
MG_'3Q%\</@3^S?XN\;_\%)?^"B6F?%GXO_"GX2>(/%NG>$_V*O@9_P`*XT[X
MA^/O"6@7^N6/AOQ/=?\`!,/7O#R^#++Q)JMU;Z1KUUXYUC1TT6.WU&X\57]D
M&U:3^@U3D`YS^&._I^G^-=>:956RC$2P^(JPJ554K0E[.ACJ,>:A)4YR4\9A
M<,JB<K<KI<ZY4I2:YHWY,NS&CF5%5Z,)0@X4IQ4ZN%J2Y:T.>'-'#8C$>SDE
MO&;B[Z*]I6:(XP00BY4DJ<#*D@J2/0X)'T)'0F@QQDDE%)/4D9/YU\4_#'XI
M^//$?[>_[7/P@UG7C>_#OX7?`?\`8[\7^!/#ITS1X!H7B+XJ:Y^U):>/=1&J
MVNGP:WJ3:];_``[\&Q?9M7U*_L],&D$Z-;Z<VHZJU]U?@WXA>,-2_;<_:$^$
M]YJ_G?#_`,&?LO\`[(WQ$\-Z`+#2XAIOC+XG?%?]MCPUXXUDZI#91ZU>'7-$
M^$7P]LOL&H:C=:7IO_"/_:=(LK"[U;7)]3B>75X>WO.D_JV7X+,9\LY^]A\=
M'`RI0A[BO4A]?HJK%\M.+A5Y9SY8<^D<;2E[*T:G[[&8C!1NHZ5<,\4JDI>^
M_<E]4J<C5Y/FAS1C>7+]5>5'_<7\J/*C'(0`]B!R#ZCWKB?B5X1UWQUX+UCP
MMX;^)?C;X0:UJ3::UE\1/AU8?#G4_&/A_P"PZK8ZC<#1[+XL^`?B?X`E_M:U
MM)M$U`Z[X'UIHM+U*]ETEM,UI-.U>P_*7X;>`_VI/%W[8G[4?[/VJ?\`!1K]
MK.+P7\%/A-^RWX]\(ZE8?#K]@&'Q1>:M\;=4_:'L/%EKXBOKG]B*[TF^T[3T
M^$7AV3P['INBZ/=6CZAK8U.[U=9[`::8/`+&4<76>.PN%6#I>VJPQ%/&SDZ4
MJV&PRG'ZMA*]/WJV*A#EG.#?+-M*/*Y3BL:\-5P]+ZIB:_UJI[&G4HO#*$:B
MI5JSC/VV(I3C:E0F^;EY&W",9.3Y5^R'E1;M^Q-V,;MHS@]L^G/3I^%25'"C
M1PQ1NP=TC1'=5*AV50K,%9G*AB"0I=R`<%F/)^"_@=\9OB5XN_X*`_M[_!3Q
M#XC&H?#+X-?#7]BKQ#\-O#7]C:!:'PYK'Q9T3X\W'Q`NSK5CI5MXAU@:_-X*
M\,N+;7]6U2TTG^S2NAP::M]J(N^>AAJE>GC*L)04<%AHXJKS.2E*G+%X3!*-
M.T97DJN,I2Y9.,53C4:ES*,)=%2M&G+#PDI7Q%1T862]V4:%;$>_=JT5"A-+
MEYGS.*M9N2^^*8$1?NKMSP-HQ@=,9`Z=.#P.U>2_M`?%[2OV?O@3\:/CQKNE
MZCKNA_!7X3_$3XM:SHFCM;)J^L:5\.?".K^+]1TO3'O9(;./4+^ST>:ULY+N
M6*V2XEC:XDCB#,/C'X6_`K]MGXK^"M)^)GQX_;5^+GP(^(?CW2M`\3:G\"OV
M</AO^R4GPP^#AO?#FB22_#NUUSXW_`;]HWQ[XW\0:'J<>HIXM\<W/Q'31/$F
MNW.H3>%/#'A/PRFE:/;[8?`NMAY8JKB:&#H1K?5H5,1]8;K5E"%2I3I0PU#$
M3?LJ=2G*K.<84H^TA%SYI\IE6Q2A56'A1K8BK[/VTH4O8VIT^9PC.;K5J,%S
MR4HP2DYRY)M1Y8R:_2<1(#D*,YSG`ZYW$].I/)/4DD]:DKR_X+^&_BCX0^%_
M@WPO\:?B7HWQC^)NA:1'I?BGXH:%\/+;X4V7C>YLY98;/7[CP!8>)O%NE^']
M;OM-2RD\2QZ'JT'AR^\1_P!JZGX;\.^#]`O=-\(Z'Q?[57[0FB_LM?`+XC?&
M_5O#VM>-;SPEI5G:>#/AUX8L=:U/Q5\4_B=XLU:P\'_"KX4>%K'P]H?B76)?
M$GQ/^(VN^&/`NB36N@ZG'8ZAKT.H7T`TZTNY8\(8>=;$PPF&MB:E6O'#X=TE
M.,:\YU%3I.FJT*4XQJMQ<%5A2FE)>TA!W2UE5A2H2Q%5.C"%)UJO/R\U*,8<
M\U/D<HN5-)J7+*4;I\LI*S?T"T:.064$CH2,XSUQZ9``/J/I3@`HP.!S^IS7
MYB?L6?&']ISPK\6O&/['_P"W)XF\,^,OCV_PW\-?M(_#+XC>`O"-SX>\!>/?
MAOKL/A_PU\9/`VC2V/AO2=#_`+3_`&<_C?J#^%+:74IK+Q=XE^$7C_X*^*M?
MTJ3Q+J'BN^/Z=G^H_F*TQV#G@*[HRJ4:\73IUJ6)PLI3PV)HU:<:E.O0G.%.
M<H23Y7SPA4A4C.E5A"I"<5&%Q,,725:,*E.5Y4ZE*M%0KT9P=I4JL5*2C)64
ME:4HRA*$X2E"49-K1HQRR@GIR!_G_/'4Y!%&.0B@^N.1]/0U\K_L[_$+QAXU
M^*O[<'AOQ-JXU+1?A!^U!X5^&WPZL1I^EV*^'?!=[^QM^R7\5[K1A/IUC:7.
MJ^;X_P#BCXZU\ZCKDVI:LO\`;G]EI?KHNF:/IVG_`%76>)PT\)5]C4<7+V6'
MK7@VX\N*PU+%4U[T8OF5.M%35K*:DDY*TG6'Q$,33=2FI1BJM>BU))/FP]>I
M0F[1E)<KG2;B[W<;-I.Z49CB4ABJY'0E02.=PP<9&",CT.3UJ0<\CH:_'K]M
M'X^^.?AQ^U#HOAWXJ_M*?&G]B[]D.+X+>&=1T/X\?"GX"_#OQKX*\3_'GQ;\
M4_$7AC7?"WQU^/?Q9^$'Q^^'GP/\.^"/"NC^`KCP5INO^#_AWI_C+4OB/XIU
M#6/B=<#POH_A=OO[]EC4DU?X)>%]2M_VE=+_`&O=.O\`5?'=WH/[06CVOPPM
M[3QOX8F^('B>3PM8S3?!>QTKX7:MJG@7PX^E?#W6_$7@W1M`TWQ/K'A2^\12
M^'=`O]4N](LNS$Y76PN!PN.G.$J>*5-T_9T\7*/OPE-P>(>%C@G6HJ*CB*-/
M%U*M&<O9R@ITZ\:7/A\?3Q&*KX6%*<7AW)3E*="+O"48O]PJKQ,82YG*G5J4
M84ZL%SPE*,Z;G]#T445YAWA1110`51U/2]-UO3[W2-8L+35-*U*VGLM1TW4+
M>*[L-0LKJ)H;FSOK.=7M[NTN87>&XMKB.2">)VCEC=&(-ZB@#X^\9_L`_L:^
M.OL!U?\`9Z^'VDMIB3QVK>!+*]^&.Y)PH9+X?#:^\)C5$C"*+=-4%XMJ-PMA
M"'<-_+-_P5J_:@^.W_!+G]N'P-\`OV%O'LOP,^$WQ#_9H^'/Q1\9^%4\/>%/
MB0VM^.KGXJ_'#PC-K9U[XO:%\0/$VGAM`\+Z)8?V9IFLV>C@V9NQ8"]N;NYN
M/[6J_@J_X.:03_P5#^"6`2?^&*?ACP.3_P`EY_:1/\@3^%?HGA?@L'C^+*&'
MQV$PV-H?4<PJ.ABZ%+$47.GAVX3=*M"<'*$O>A+EO&2333/EN,,1B,-E$:N%
MKUL/4^OX"#J4*LZ4^2>(BIQYX2C+EDM)1O:2T::/1OAK^W+^V#\>+O0V^(O[
M1_Q;D^R7$-R@\$>+]2^$R3.\T<C1WL?PFD\$1ZA:LR(&LK]+FS>-%C:`IE3^
M\_P1EE^)FB:9K_Q'EE^(&O>$+&[U'PKKGC:1_%6L^&]1N;-+.XU#0M4UUK^^
MTJ^GM9'MYKNQG@N)87:-Y&5B#_/M^P[^R+^U'\1K'3O$/@WX"?$O4M`G\,6_
MB[1O$>J:#_PA_A/Q1HSNBVLGA/QEXYN?#/A#Q)<7SE/L=KI.NW,TL,GVXJNG
MQSW<7]1'[/O[*/Q7\.>%[:T\9ZOH'@J#4]*TPWMKI$G_``D_C*TM]4\/:I'K
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MCQ`D&IZ[K-I!KFOSA]2U"QTO4O$_B*;0=)DG_L;PS!K%[IOAK3])TITL4])K
M\\S+B'$XS`TLJH.5#+Z;A.I'15,54A;D=:VU*FUS0I7:Y[5)MSC3]GZ=/#QC
M4=67O3UY?[B>]GU<M+M[;+NRODGXU?LQ3_%S]I;]C;]H./QFF@Q?LF^)?C5X
MCD\*-X?_`+3;QX?B]\&_$/PD6R76_P"W-._X1G_A'QX@;Q`;G^R/$']J?8QI
M/D:=]I_M.W^MJ*\.A7JX:HZM&7)-T<3AV^6,KTL7AZN%Q$+2C)+GH5JD.96E
M&_-%J236M6E3K14*D>:*J4JJ6JM4H585J4M.L*M.$ET=K---IH!@5X=^T[\'
MI?VAOV;OC_\``*'71X6E^-_P5^*/PBC\3MI@UI?#;_$GP3K?@T:^VC'4M'_M
M==&_MDZB=+_M?2SJ`MC:#4+(S"YC]RHJ:56=&K3K4GRU*52%6G*RERSA)2@[
M23B[22=I)I[--#G3A4ISI35X5(2ISCM>$DXR6EFKIM:'B?[.GPC?X#_L\?`[
MX%R:W_PE$OP:^#GPW^$__"2G3AHH\1GX>>"]&\(#7O[&74=8&C_VR-(&H'2O
M[6U4:=]I^Q_VC?>3]JE;^S-\'W_9Z_9Q^`'P#?7SXK?X(?!3X5_"!O%)TI="
M_P"$E/PU\"Z#X+.O_P!AKJFMKHW]L_V+_:/]E#6=6&G?:?LG]IW_`)/VJ7VZ
MBM)XO$5(UX3J<T<3B(XJNN2"YZ\?;6G[L5R6^L5?<ARP][X?=C;..&HQJ4ZL
M86G2HSP]-\TK1I5)4I2C:]GK1IVDTY)1LG9N_P`#_M9_L)>&_P!L_P"*WP%U
M?XT^--<NO@+\";KQ!X_L?@EX3G\0>!]2\7?'F>*#1?`?Q-\0?%CPGXMT?QAI
MNG_"WPQ?^,1X0\-^#8?#.I'Q9XG_`.$@U;Q=J&FZ?%X:E\K\6?\`!*?X(Z7\
M0_@9\<OV?_$?Q+^$OQ[^`/Q-T[QCX/\`B!XO^*?Q>_:)TR]\$:U:77A;XQ_"
M;5_!OQW^)OB_2[/PS\6_AYJFJ^'-1UWP?=>%/&?AO7(O#/BW2-=F/AR30=9_
M4RBNRCG6:X>E0H4<=7IX>A3JT8X:,O\`99TJ\ZLZ].OAFG0Q"KNM4C6]O3J2
MJTFJ,W*E"$(\]7+,!6J5*M7"TIUJM6E6=:4;UH5:"IJC.E5?[RBZ7LH2I^RE
M!0J)U8I5)3E)B[M@W`EN"1D'D>_3^7X5\2ZW^Q)\/?B/X1_;6^'7QBCM?'OP
M]_;0^(EAXY\0^';G1;.TN/!<>G_L^_`/X(Z?#HNISW^LI<^*/#VL_`G3?BCX
M/\<0:?HNH^%/%=]HL^DV*:GX2M=>U'[=HKCPV+Q&$<I8:M.C.:IIS@TJB]C7
MHXFE*%2W/3G"O0HU8U*<HS4H+WK-I]%;#4,1R*M3510=3EC+6-JM&I0J1E%^
M[4C.E5G!QFI1=[VYDFO&/V??!GQ3^'7P@\">`_C-\3K+XT_$/PEH5OH&O?%B
MT\&GX?S>/WTV6XMK'Q)K/A/_`(2OQK#I_B>_TJ/3G\5W=EK[:7KGB7^U=>TK
M1O"VG:E;>%M&P/C9\#Y?C!XU_9G\5?\`"0G08OV=_CO<?&MK+^R4U4>,1=_`
MGXY?!)_#!N?[7TQ_#_E#XRCQ/_;0MM;WCPZVBC25;5AJNF_0U%"Q5=8BIBH2
MC3K577YG2HT:5-+$QG"M&%"G3C0IPE3J3A&G3IQIPA+EIQC:-B6'I2HTZ$E*
M5.G['DYJE24[X>I"I2E*K*3J3DI4X\TIRDZBYE4YN9W_`#>^&W_!.7P%\/OV
MS?'G[6#^+=;\1:-?7'C[Q;\'/@MK&C>&KKPA\!_B_P#'>V\'V7[3/Q8\">(;
MBTG\70:[\:K?X>^%Y;G38-0TS3?#5[XB^-<D/]KVWQ@U*UT;VK]AO]F";]C?
M]FGP7^SS+XT'Q!/@_P`2?%O7QXL'AT>%/[1_X6C\9/'_`,61;?V$->\3?9!H
MB^.!H'G'6;@ZE_9?]J&#3_MO]G6GUO173B<VS#&4?88K$SK4O]C7+.-/;`4L
M51PVL8)WBL;BJE62?/B<16GB<3*K7?M#*AE^$PTU5HT5"HGBK3YIM_[9/#5,
M0K2DXVD\)AXP5K4J=*%&ER4HQ@OB?]L/]D$?ME2?!OP'X^\=7NE_L[>#_B!/
M\1?C%\*O#_\`PG'AOQ%\;-0\.Z!>CX4:#+\3_`WQ0\$ZEX/\*^"/B'=6'Q.U
M72?^$:\4W7B7Q1X/\"3Z=JWA&30)[G4_`OBY_P`$G?@KKOA[1=8^`OC7XO\`
MP0^/7P\\:>#_`(E?!GXQZ_\`'+]I#X]6'P[\=>$=<M+QM0N/A7\4_CQ=^"O%
MVE^*/"LGBCX=>*M%U<00ZKX*\:^)M*-S$M^[5^JM%7ALZS7!0PU+"XZOAZ.%
M;E"A2ER4*DI5'4J/%4$O98QUK^RK/%PK>UP\:>%J<V&ITZ4<ZV5Y?B)UJE?"
MTJU6NHJ56I%2JP4(*$/857^\P_L[<]/V,H<E:4ZT.6K.4W%$)1$HE(:4`AV7
M`#$9&X`<+NX('.W."21D_`GC?]EGXW^$?C]\1?VB_P!DWXW:!\/M9^-6F^&V
M^.7P;^-?@KQ-\6_@=\0O&'@K2?#?A'PI\3O"-GH/Q.^'OBGX*?%9?ASX8TKX
M<>*_$GAF\\2>!_&_A?1?!EQXG^%VI^*?!NG>(Y?T`HKCPV*K8251T7"U:DZ%
M:G4I4JU&M1<X5/9U*5:$Z<DJE.G4@^53I5(0JTI0J0A./37PU+$J"J*5Z<U4
MI3IU)TJE*HDXJ<*E.491?+)Q:ORRBY0FI0DXOY=^$'@[]K*'Q[JWC/X_?&KX
M;:MX7?PV^A^&?@Q\&OA+-X2\*Z7JD^L17USXP\7_`!!\=>,?'_C[QOXD@TZR
MM])T&'PVGPG\(:99:IXB&N^$/%^JOX=UWP]]'ZU8G5-'U73`YC.H:=>V(D"A
MS&;NVD@WA&DB5RGF;@AEC#$8,B`[AIT5-6O.K455JE3E%1451H4:$(\GPOV=
M*G"#DOM3E&4YO6I*;U+ITHTH<D74DFVW*K6JUIMRW]^K.<HIO50BXPA>T(QC
M9+\S?@A^S3^WO\`?@G\(?@5X,_:N_9+U+PI\&/ACX`^%'AC4/$G["?Q<O/$-
M_P"'OAYX6TGPAI%[KM[IO_!1+2--NM9N=-TBWN-2N;#1M,LIKUYI+33+.!H[
M6+],5&`!]?YTM%:8O&U\=5E6Q'L75G.I4G.EAL-AG.=67-.4_JU&DIRE+6\D
M[-OEM=WRPN$HX.FJ5!UO9QA3IQC5Q%>NH0I1Y(1A[:I4Y4HV7NVNDKWLCX-^
M*/[-GQWTS]IG4/VI?V9?BUX"\*ZWXZ^%O@SX2_&KX3?%KX;3^+O`_P`1=)^&
M?BGQ5XA^&?B_PYXP\*>)_!_C?X<^/O"4'Q*^)NBW]Y=?\+!\'^+-#UO0K*\\
M%Z9JGAFRU^3HOV9_V=?BU\//B?\`'+]H#]H#XP:'\5/C#\=-(^$W@^;2_`/@
M&?X<?"?X7_#7X,V7C"Y\'^!_`N@ZUXN^(/C'4[RX\9?%#XI>,?%WC#Q/XTNF
M\1:CXHLX-'\+^#=-T:/3KG[0HK:>9XN="6'E*ERSP]'"U*D<-AXXBIAJ$Z52
MC0J8B-)5IPIRH4+.4W-PHTJ4I.E3C!1'`8>-95TJG-&K4KQINM4=&%:JIJI5
MA1<O9QG-5*G,U'XJE2:2G.4F5\V>!/@%-X,_:A_:$_:+;Q.-0B^.?PV_9]^'
MR>$_[%%H?#)^!.I?&S4/[6.N_P!L71UG_A*?^%R-$+#^Q=)&B#PV)/MNK'6/
M*TKZ3HKEIUZM&&(ITY<L,51C0KJR?/2C7H8E1U3<;5L/1GS1M+W>6_+*2?1.
ME3J2I3G'FE0J.K2UDE&;I5*+E9-*7[NK-)232;YDN9)HKY8^&7[-;_#S]JS]
MJ7]IIO&0U8?M)^#?V</"*^"O^$>^PGP;_P`,_P"F_%&Q;4#XC_MV]_X2'_A+
M#\2O,%I_86A_V%_8FW[3K`U(-8?4]%%*O5HPQ%.G+EABJ*P]=<L7ST8XBABE
M"\HMPM7PU"?-!QE[G(Y<DIQD3I0J2HSFFY4*CJT]6K3=*K0;:37,O9UJD>65
MXWDI6YHQ:X_XA>`?"/Q5\`^-_A?\0-&A\1^`_B/X0\2^`O&OAZXN+VTM]>\(
M^,-%O?#WB31I[K3KFSU"WAU31M1O;&6>QN[6\ACG:2VN()E21?@CX9?L_?MW
M_L\^`?#OP3^%'[1_P+^)WPN\"^&]/\#_``N\2_M"_`KQ7=?&+P5X1T`VVF^%
M;+QYKWPJ^,?@+P9\;I_#OA:&#0K:^LO!/P2UO6%TJRO_`!/KFM:Y>:KKMY^D
M]%;8?'8C#4IT(>RJ4*DXU)4<1AZ&(IJK!652"K4YNE-Q]R<J3A[6"4*O/&,%
M'*MA*5:I&J_:0JPBX*I1JSI2<)-2<)\DDJD;Q3BIJ7(VY0Y9-M^8_!_PS\2?
M"/@+2]'^+OQ/C^,'Q"^V:UJ7B#QO:>"-%^'&D7$NLZS?ZK:Z)X<\%Z+>:NNA
M>%_"ME>6WAGPW;ZSXD\7^*I-%TFRN?%GC/Q9XBFU+7K_`.6?VM?V%O#/[9_Q
M,^`^H?&GQ?KE_P#`;X':CX@\?P?`[PR^L^#+KQC\<KFTCT/P#\4=>^+'ACQ7
MI'C71K?X2>';_P`8OX/\.>"(O#.IS^+?%,7B/5O&%WI^AP>&KK[THI4<=BL-
MB7C,-5^KXE^VM5H0IT'3=>$Z=25"-*$(8:2C4E[*6'C2EAY6EAW2E"#B5<)0
MKT(X:M!UJ$71;A5G.IS^PG"I3564Y2E67/"+FJKFJMFJJFI23_+3Q7_P2G^"
M.F>/_@G\;/@!XD^)/PD^//P&^)&G>,/!?Q#\8_$_XO?M':9/X.U6UN/#/Q?^
M%.J^#/CM\4/%5C8^&/B_\.M3UCPKJVN>!]2\%^-=`UA/"WBK3?$5Q'X:E\/Z
MS^I0R1R.?\#UX_SVI:*,5CL9CHT5C,36Q7U>-2G1G7E[2K"G4DINE[:5ZLJ4
M9\TZ=.<Y0I3JUI4E!U:G,8?!X;"NJ\-1A05:495(4DH4Y3C'D53V4;4XU'!1
MA*<8J4XPIJ;ER1M\"M^SO^UCX(^+G[17CWX%_M$?L_\`A3PC^T'\4_#OQ;O_
M``E\5OV3_B%\5O$/AKQ#HOP'^"_P)NK*S\:>$OVR_@IIVHZ/J&F_!;2?$%O;
MS^!K:]T^^UG4;*34-1@@MYS]M>%+?Q1:>&=`M?&^KZ'K_C&WTC3X?%&N>&?#
MM]X1\.:OKR6T:ZKJ.@^%=3\3^-=2\.:1=WHFGT[0[_QCXKO=+M'BLKKQ'K4\
M+ZC<]!11B<=B,6J:KNC+V5.E2C*&%PE&HX4*,*%)5*U&A3JU>2C3A"]6<W*W
M//FG>04,+2P\JCI>TBJDZM24)5JLZ:G6JRK5)0ISG*%/FJ3E*U-1BN9I)+0^
M2OB]X1_;-D^(MQXF^`WQ?^!T'P[U/P1I7AVY^$OQF^$'B76_["\96%]XWN[W
MXC>'_B5X%^)7A36YX]>M=<\(:-KG@#Q!X8U;37L_!4%YX=\2^%=0UK6Y+WG/
MV&?V/T_8Z\"?%S1+[QM!X_\`&7QV_:.^+O[3GQ(UO1O",?P]\$6OCKXN7^ER
MZAH7PX\`'Q%XTO\`P=X&T32]#T;3],TC6O'7C76IKZ'4]7OO$4YU.*QL/MBB
MJ>/Q+PKP2=&G0G['VJHX;#T:E?V%W1]O5ITHU*O(Y.3<I-U)VG5YYQC))8.@
ML2L4_:3K1]I[-U*U6I"C[:WM52ISFX04[+11]Q*U/DBY)E%%%<1U!1110`44
M44`%?E;XT_8)\!_&K_@JU!^V+\8/`:>+-#^!G[(GP-\%?`]?$%G;:AX,;XN7
MGQJ_:7\3>*_%#:=<!X=0\6_"[0'\$W/AH:A#=:?HNH?$&U\5V-M%XLT#PQK&
MB_JE1BNS!X[$X!XB>%JSHU,1A:V$G4IR<9QHU^55HQDMO:TU*C/O3J36E[G/
MB,-1Q2I1KPC4C2K4\1&,E>/M:3;IR:Z\DFIQOIS13::T$`"C```]!P.>:6BB
MN/\`X8Z`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
